These results are consistent with other studies that have reported increased postprandial GLP-1 levels following administration of either (i) following a single dose of acarbose or following 2 weeks of acarbose treatment in both normal subjects and those with T2D [7,8,16,17], or (ii) acarbose in combination with alogliptin (a DPP-4 inhibitor) [18]. This evidence concerns the gene GCG and type 2 diabetes mellitus.